Effects of (-)-tertatolol, (-)-penbutolol and (±)-pindolol in combination with paroxetine on presynaptic 5-HT function:: an in vivo microdialysis and electrophysiological study

被引:50
作者
Gartside, SE
Clifford, EM
Cowen, PJ
Sharp, T
机构
[1] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
[2] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England
关键词
SSRI; antidepressant; paroxetine; beta-adrenoceptor/5-HT1A receptor ligands; (+/-)-pindolol; (-)-tertatolol; (-)-penbutolol; 5-HT cell firing; extracellular; 5-HT;
D O I
10.1038/sj.bjp.0702546
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The antidepressant efficacy of selective serotonin reuptake inhibitors (SSRIs) might be enhanced by co-administration of 5-HT1A receptor antagonists. Thus, we have recently shown that the selective 5-HT1A receptor antagonist, WAY 100635, blocks the inhibitory effect of an SSRI on 5-HT cell firing, and enhances its ability to elevate extracellular 5-HT in the forebrain. Here we determined whether the beta-adrenoceptor/5-HT1A. receptor ligands (+/-)-pindolol, (-)-tertatolol and (-)penbutolol, interact with paroxetine in a similar manner. 2 Both (-)-tertatolol (2.4 mg kg(-1) i.v.) and (-)-penbutolol (2.4 mg kg(-1) i.v.) enhanced the effect of paroxetine (0.8 mg kg(-1) i.v.) on extracellular 5-HT in the frontal cortex, whilst (+/-)-pindolol (4 mg kg(-1) i.v.) did not. (-)-Tertatolol (2.4 mg kg-l i.v.) alone caused a slight increase in 5-HT however, (-)-penbutolol (2.4 mg kg(-1) i.v.) alone had no effect. 3 In electrophysiological studies (-)-tertatolol (2.4 mg kg(-1) i.v.) alone had no effect on 5-HT cell firing but blocked the inhibitory effect of paroxetine. In contrast, (-)-penbutolol (0.1-0.8 mg kg(-1) i.v.) itself inhibited 5-HT cell firing, and this effect was reversed by WAY 100635 (0.1-0.8 mg kg(-1) i.v.). We have recently shown that (+/-)-pindolol inhibits 5-HT cell firing via a WAY 100635-sensitive mechanism. 4 Our data suggest that (-)-tertatolol enhances the effect of paroxetine on forebrain 5-HT via blockade of 5-HT1A autoreceptors which mediate paroxetine-induced inhibition of 5-HT cell firing. In comparison, the mechanisms by which (-)-penbutolol enhances the effect of paroxetine on extracellular 5-HT is unclear, since (-)-penbutolol itself appears to have agonist properties at the 5-HT1A autoreceptor. Indeed, the agonist action of (+/-)-pindolol at 5-HT1A autoreceptors probably explains its inability to enhance the effect of paroxetine on 5-HT in the frontal cortex. 5 Overall, our data suggest that both (-)-tertatolol and (-)-penbutolol are superior to (+/-)pindolol in terms of enhancing the effect of an SSRI on extracellular 5-HT. Both (-)-tertatolol and (-)-penbutolol are worthy of investigation for use as adjuncts to SSRIs in the treatment of major depression.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 51 条
[1]   SEROTONIN-CONTAINING NEURONS IN BRAIN - DEPRESSION OF FIRING BY MONOAMINE OXIDASE INHIBITORS [J].
AGHAJANIAN, GK ;
GRAHAM, AW ;
SHEARD, MH .
SCIENCE, 1970, 169 (3950) :1100-+
[2]  
AGHAJANIAN GK, 1982, J NEUROSCI, V2, P1786
[3]   5-HT1A RECEPTORS IN THE MEDIAN RAPHE NUCLEUS AND DORSAL HIPPOCAMPUS MAY MEDIATE ANXIOLYTIC AND ANXIOGENIC BEHAVIORS RESPECTIVELY [J].
ANDREWS, N ;
HOGG, S ;
GONZALEZ, LE ;
FILE, SE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 264 (03) :259-264
[4]  
[Anonymous], 1992, Monitoring Neuronal Activity: A Practical Approach
[5]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[6]  
ARTIGAS F, 1994, ARCH GEN PSYCHIAT, V51, P248
[7]   Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord [J].
Arvieu, L ;
Mauborgne, A ;
Bourgoin, S ;
Oliver, C ;
Feltz, P ;
Hamon, M ;
Cesselin, F .
NEUROREPORT, 1996, 7 (12) :1973-1976
[8]   (-)-Pindolol and (+/-)-tertatolol affect rat hippocampal 5-HT levels through mechanisms involving not only 5-HT1A, but also 5-HT1B receptors [J].
Assie, MB ;
Koek, W .
NEUROPHARMACOLOGY, 1996, 35 (02) :213-222
[9]  
Berman RM, 1997, AM J PSYCHIAT, V154, P37
[10]   CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].
BLIER, P ;
DEMONTIGNY, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226